VENEZE peptide hair serum versus 2% topical minoxidil for androgenetic alopecia

Effectiveness and Tolerability of VENEZE Peptide Factor Hair Serum for Pattern Hair Loss: A Randomized Double-blind Study

This trial tests if VENEZE peptide hair serum helps adults with androgenetic alopecia grow thicker, denser hair compared with 2% topical minoxidil.

Quick facts

• Phase: Not applicable
• Study type: Interventional
• Enrollment: 80 (estimated)
• Ages: 18 Years and up
• Sex: All
• Sponsor: Institute of Dermatology, Thailand (Government)
• Locations: 2 sites (Bangkok, Bangkok and 1 other locations)
• Trial ID: NCT07536100 on ClinicalTrials.gov

What this trial studies

This is a randomized, double-blind, parallel-group comparison of a peptide-based topical serum against standard 2% topical minoxidil in adults with androgenetic alopecia. Participants are randomly assigned to one of the two treatments and followed over a defined treatment period with regular in-person visits. Primary outcomes are objective measures of hair growth, including hair density and hair thickness, and secondary outcomes include safety, tolerability, and patient-reported measures. The protocol requires consistent hair styling and measures to limit confounding factors affecting hair growth.

Who should consider this trial

Good fit: Adults aged 18 or older with androgenetic alopecia (men Norwood-Hamilton III–V or women Ludwig I–II), at least 2 cm hair in the non-balding vertex area, and ability to attend visits for the 24-week protocol are ideal candidates.

Not a fit: People with hair loss due to other causes (for example scarring alopecia), unstable systemic disease, recent malignancy, or very advanced baldness are unlikely to benefit from this topical comparison.

Why it matters

Potential benefit: If successful, the peptide serum could provide an alternative topical option that increases hair density and thickness with comparable or improved local tolerability compared with minoxidil.

How similar studies have performed: Topical minoxidil has well-established efficacy, while peptide-based hair serums are a newer approach with limited clinical trial data and few direct head-to-head comparisons.

Eligibility criteria

Inclusion Criteria:

* Male or female participants aged ≥18 years.
* Diagnosed with androgenetic alopecia (AGA): Norwood-Hamilton classification III-V in males or Ludwig classification I-II in females.
* Able to read and write for completion of study questionnaires (e.g., Patient Global Assessment, Hair Growth Questionnaire).
* Willing to comply with study procedures, including maintaining consistent hair color and hairstyle throughout the study.
* Hair length in the non-balding area (vertex surrounding area) ≥2 cm at each visit.
* Able to attend all scheduled visits during the 24-week study period.

Exclusion Criteria:

* Presence of unstable or uncontrolled systemic diseases that may affect hair growth or loss within 6 months prior to screening (e.g., liver, renal, thyroid, cardiovascular, neurological diseases, diabetes, anemia).
* History of malignancy within the past 5 years, except adequately treated basal cell carcinoma or squamous cell carcinoma.
* Psychiatric disorders or other conditions that may affect participant safety or compliance.
* Pregnant or breastfeeding women.

Hair and scalp-related exclusions:

* Diffuse hair thinning involving the occipital area.
* Scalp conditions or diseases affecting hair growth (e.g., tinea infection, non-AGA hair loss, psoriasis, uncontrolled seborrheic dermatitis).
* History of hair transplantation at any time or hair extensions within 6 months prior to screening.
* Use of cosmetic products for hair loss concealment within 2 weeks prior to screening.
* Use of light/laser therapy on the scalp within 3 months prior to screening.
* Use of supplements related to hair growth (e.g., zinc, biotin) within 3 months prior to screening.
* Use of hair products containing active ingredients (e.g., caffeine, peptides) within 3 months prior to screening.
* Hair procedures such as mesotherapy or stem cell injection within 3 months prior to screening.

Medication-related exclusions:

* Known hypersensitivity to study-related products or ingredients.
* Use of dutasteride within 12 months prior to screening.
* Use of systemic cytotoxic agents.
* Use of systemic glucocorticoids within 3 months prior to screening (except inhaled or topical corticosteroids not applied to the scalp).
* Use within 6 months prior to screening of:

  * Minoxidil (topical or oral)
  * Finasteride (topical or oral)
  * Anti-androgenic drugs (e.g., spironolactone, cyproterone acetate, flutamide, bicalutamide)
  * Prostaglandin analogs applied to the scalp
  * Estrogen or progesterone topical preparations
  * Tamoxifen
  * Drugs associated with hypertrichosis (e.g., cyclosporine, phenytoin)
  * Drugs associated with hair loss (e.g., valproic acid)
* Participation in another clinical trial within 1 month prior to screening or during this study.

Where this trial is running

Bangkok, Bangkok and 1 other locations

• Institute of dermatology — Bangkok, Bangkok, Thailand (Recruiting)
• Institute of Dermatology — Bangkok, Thailand (Recruiting)

Study contacts

• Principal investigator: Chinmanat Lekhavat, MD, PhD — Institute of Dermatology
• Study coordinator: Chinmanat Lekhavat, MD, PhD

Conditions Androgenetic Alopecia; Androgenetic alopecia; Peptide hair serum; Minoxidil